Filing Flows › Bruker (BRKR) › Q2 2026 › vs Q2 2025
Bruker (BRKR) Q2 2026 vs Q2 2025 (year over year)
Bruker's revenue rose $41.1M (+5%) from $797M in Q2 2025 to $838M in Q2 2026. The biggest changes: Bsi Calid +$24.5M (+9%); Bsi Nano +$9.2M (+4%); Energy and Supercon Technologies +$7.0M (+11%).
Bruker, Q2 2026: revenue $838M (+5% year over year), operating margin -7.8%, net loss $50.9M, operating cash flow −$77.4M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Bsi Calid | $310M | $286M | $24.5M | +9% |
| Bsi Nano | $261M | $252M | $9.2M | +4% |
| Bsi Biospin | $196M | $195M | $400K | +0.2% |
| Energy and Supercon Technologies | $71.2M | $64.2M | $7.0M | +11% |
| Revenue | $838M | $797M | $41.1M | +5% |
| Other income, net | $28.6M | −$10.8M | $39.4M | — |
| Net loss | $50.9M | −$4.2M | $55.1M | — |
| Costs & expenses | $918M | $800M | $118M | +15% |
| Operating costs | $904M | $786M | $118M | +15% |
| Income tax | $14.2M | −$3.1M | $17.3M | — |
| Cost of revenue | $422M | $440M | −$17.0M | -4% |
| Research & development | $94.3M | $100M | −$5.9M | -6% |
| SG&A | $239M | $231M | $7.5M | +3% |
| Other operating costs | $148M | $14.4M | $134M | +928% |
| Operating cash sources | $141M | $189M | −$48.3M | -26% |
| Depreciation & amortization | $58.0M | $56.1M | $1.9M | +3% |
| Share-based compensation | $5.6M | $5.7M | −$100K | -2% |
| Cash used in operations | $77.4M | $128M | −$50.1M | -39% |
| Net loss absorbed | $50.9M | −$4.2M | $55.1M | — |
| Working capital & other | $90.1M | $194M | −$103M | -53% |
Questions
How much did Bruker's revenue grow year over year in Q2 2026?
Bruker's revenue rose $41.1M (+5%) from $797M in Q2 2025 to $838M in Q2 2026.
What drove Bruker's revenue change in Q2 2026?
Bsi Calid +$24.5M (+9%); Bsi Nano +$9.2M (+4%); Energy and Supercon Technologies +$7.0M (+11%).